0001193125-26-449826 | 10-Q | XBRL Viewer

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2026

Commitments and Contingencies Disclosure [Abstract]

Schedule of Minimum Purchase Obligations

As of September 30, 2026, the timing of minimum purchase obligations with these vendors was as follows (in thousands):


2026 (remaining)	$	38,901
2027		49,236
Total minimum purchase obligations	$	88,137

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2026
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The U.S. dollar is the Company’s functional and reporting currency.
Principles of Consolidation	Principles of Consolidation In September 2026, the Company incorporated a wholly-owned, Netherlands-based subsidiary, Vera Therapeutics B.V., to help prepare for and assist with the Company’s activities in Europe. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. For the Company and its subsidiary, the functional currency has been determined to be in U.S. dollars.
Unaudited Condensed Financial Statements	Unaudited Condensed Consolidated Financial Statements In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the periods presented. Interim results are not necessarily indicative of results for a full year or any other period. The information included in this Form 10-Q should be read in conjunction with the audited financial statements and related notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the accrual of research and development expenses, valuation of equity awards for stock-based compensation, determination of incremental borrowing rate for operating leases, the valuation allowance for deferred tax assets, fair value of marketable securities, gross-to-net reserves for revenue recognition, and inventory valuation. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation, with no impact on previously reported net loss or total assets.
Concentrations of Credit Risk and Other Risks and Uncertainties	Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by any of the financial institutions holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations. For the three months ended September 30, 2026, two individual customers accounted for 94% of total gross product revenue, with these individual customers representing 76% and 18% of the Company’s total gross product revenue. As of September 30, 2026, two individual customers accounted for 94% of the gross accounts receivable balance, with these individual customers representing 76% and 18% of the gross accounts receivable balance. No other individual customers account for more than 10% of net product sales or accounts receivable. The Company monitors the financial condition of its customers so that it can appropriately respond to changes in their creditworthiness. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable. The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s lead product or product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on single-source suppliers for some components of its supply chain. If any of the single source suppliers fails to satisfy the Company’s requirements on a timely basis, it could suffer delays in its clinical development programs and commercial launch activities, which could adversely affect operating results. TRUTAKNA is the Company’s only FDA-approved product and the success of its business depends, in part, on successful commercialization. In addition, the Company’s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any approved product, it could have a materially adverse impact on the Company.
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable consists of trade receivables which are amounts due from the Company’s specialty pharmacy and specialty distributor customers related to product sales. The Company records trade receivables net of discounts, chargebacks, and any allowances for potential credit losses. Trade receivables are stated at their net realizable value. The Company estimates the allowance for credit losses using the current expected credit loss model. Under this model, the allowance for credit losses reflects the Company’s estimate of lifetime expected credit losses. The Company evaluates the collectability of the cash flows based on the risk of loss over the contractual life, even when that risk is remote, based on judgments about the creditworthiness of its customers, historical experience, and other relevant information that is available to the Company. The Company writes off trade receivables and related allowances for credit losses when it becomes probable it will not collect the amount receivable. For the three months ended September 30, 2026, the Company did not record any expected losses related to outstanding accounts receivable. There was no allowance for credit losses as of September 30, 2026.
Inventory	Inventory The Company began capitalizing inventory for TRUTAKNA upon approval by the FDA in July 2026 once commercialization was considered probable and the future economic benefit was expected to be realized. Prior to regulatory approval, all direct and indirect manufacturing costs for pre-launch inventory were charged to research and development expense in the periods incurred. Any eventual sale of previously expensed (“zero-cost”) inventories may impact future gross margins for any periods in which those inventories are sold. Inventory is comprised of raw materials, work-in-process and finished goods, and includes costs related to raw materials purchases, third-party contract manufacturing, shipping and handling, and product storage. The Company values inventory at the lower of cost or net realizable value and determines the cost of inventory using the specific identification method, which approximates a first-in, first-out basis. Certain raw materials and work-in-process inventory may be used in the manufacture of product for either research and development activities or commercial sale. Costs related to such inventory are initially capitalized as inventory and are expensed to research and development expense once a determination is made that product is to be used in research and development activities. The Company analyzes its inventory levels periodically for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as cost of sales in the Company’s Consolidated Statements of Operations and Comprehensive Loss.
Intangible Assets, Net	Intangible Assets, Net Finite-lived intangibles consist of contractual payments made in conjunction with license agreements for acquired intellectual property. The contractual payments are recorded as intangible assets at cost, net of accumulated amortization, and are amortized over their estimated useful life of the underlying intellectual property using the economic consumption method if anticipated future revenue can be reasonably estimated. The straight-line method is used when revenue cannot be reasonably estimated. Amortization of finite-lived intangibles is recorded in cost of sales in the Company’s Consolidated Statements of Operations and Comprehensive Loss. The economic consumption method is based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenue of the Company’s marketed products is performed annually during the Company’s long-range planning cycle and whenever events or changes in circumstances would significantly affect anticipated lifetime revenue of the relevant products. The Company reviews its finite-lived intangible assets at least annually and when events or circumstances may indicate that the carrying value of these assets is not recoverable and exceeds their fair value. The Company measures fair value based on the estimated future undiscounted cash flows associated with these assets in addition to other assumptions and projections that the Company deems to be reasonable and supportable. If it is determined that an intangible asset becomes impaired, the carrying value is written down to its fair value with the related impairment charge recognized in the Company’s Consolidated Statements of Operations and Comprehensive Loss in the period in which the impairment occurs. The Company has not recorded any impairments of intangible assets to date.
Product Revenue, Net	Product Revenue, Net The Company recognizes net product revenue from TRUTAKNA, which it began selling in the United States in July 2026 through contractual arrangements with its specialty pharmacy and specialty distributor customers. These customers subsequently resell the Company’s products to patients and certain medical centers or hospitals. In addition to distribution agreements with these customers, the Company enters into arrangements with governmental and contractual payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes net product revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (ASC 606), which outlines a five-step process for recognizing revenue from contracts with customers: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the separate performance obligations in the contract, and (v) recognize revenue associated with the performance obligations as they are satisfied. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has determined that the delivery of TRUTAKNA to its customers constitutes a single performance obligation. There are no other promises to deliver goods or services beyond what is specified in each accepted customer order. The Company recognizes revenue from product sales when a customer obtains control of the Company’s product, which occurs at a point in time upon delivery of the product to the customer. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with the Company’s customers do not exceed one year and therefore the Company has elected to apply the practical expedient and no amount of consideration has been allocated as a financing component. Revenue from product sales is recorded at the net sales price (transaction price), which includes deductions based on estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company's sale of its products. These reserves, as detailed below, are based on the related sales, and are classified as reductions of accounts receivable, net, when the right of offset exists in accordance with ASU 2013-1, Balance Sheet (Topic 210): Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities, or as a current liability. These estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. These estimates are based on limited historical experience and may rely on expected payer mix, contractual terms, and peer company analysis. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company's analysis also contemplated application of the constraint in accordance with the guidance, under which it determined a significant reversal of revenue would not occur in a future period and the transaction price will not be reduced further. Actual amounts of consideration ultimately received may differ from the Company's estimates. The Company will disclose significant judgments and estimates to variable consideration and timing of revenue recognition. If actual results in the future vary from the Company's estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances — The Company generally provides customers with discounts, which include incentive fees that are explicitly stated in the Company's contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The reserve for discounts is established in the same period that the related revenue is recognized, together with reductions to accounts receivable, net, on the balance sheets. Distribution Fees — The Company pays fees to our specialty distributor customers for distribution services provided in connection with the sales of TRUTAKNA. These specialty distributor fees are based on a contractually determined fixed percentage of sales. These payments are recorded as a reduction of revenue within the same period the related revenue is recognized. Product Returns — Consistent with industry practice, the Company offers its customers limited product return rights for damaged and expiring product, provided it is within a specified period around the product expiration date set forth in the applicable individual distribution agreement. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as a reduction to accounts receivable, net on the balance sheets. The Company estimates product returns using its own sales information, including its visibility into the inventory remaining in the distribution channel. Chargebacks and Discounts — Chargebacks for fees and discounts to a third party represent the estimated obligations resulting from contractual commitments to sell products to contracted third parties at prices lower than the list prices charged to its customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the contracted third parties. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and a reduction to accounts receivable, net, on the balance sheets. Chargeback amounts are generally determined at the time of resale to the contracted third party by customers, and the Company generally issues credits for such amounts within a few days after the customer's notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to contracted third parties and chargebacks that customers have been claimed, but for which the Company has not yet issued a payment. Government Rebates — The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which will be included in accrued expenses on the balance sheets. The Company's liability for these rebates will consist of invoices received for claims from prior periods that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. Commercial Rebates — The Company calculates the rebates it incurs according to any contracts with certain commercial payors and deducts these amounts from its gross product sales at the time revenues are recognized. Allowances (accrued) for commercial rebates are based on historical payments to payors from which is reasonably estimated at the time of delivery. Rebates are recorded as accrued expenses in the balance sheet. Co-pay Assistance — Other incentives the Company offers include voluntary patient assistance programs, such as the co-pay assistance program, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors. The calculation of monthly co-pay assistance will be based on an estimated number of claims for the period and the estimated cost per claim associated with product that has been recognized as revenue.
Cost of Sales	Cost of Sales Cost of sales includes the cost of inventory sold, indirect labor costs, product shipping costs, amortization expense of finite-lived intangible assets associated with acquired intellectual property, and third-party royalties payable on the Company’s net product revenue. Cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, and manufacturing variances. Prior to regulatory approval, all direct and indirect manufacturing costs for pre-launch inventory of TRUTAKNA were charged to research and development expense in the periods incurred. As a result, the cost basis of inventory available for sale at the time of approval was zero, and cost of sales is correspondingly low during the initial period following launch. Following FDA approval, the Company capitalizes direct manufacturing costs as inventory and recognizes these amounts in cost of sales when the related inventory is sold. Accordingly, cost of sales for the period may not be indicative of the full cost of units sold, and cost of sales and gross margin during the initial periods following commercialization may not be representative of future periods as the Company begins capitalizing and expensing post-approval manufacturing costs.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This update will provide all entities with a practical expedient in developing reasonable and supportable forecasts as part of estimating expected credit losses by assuming that current conditions as of the balance sheet date do not change for the remaining life of the asset. The ASU is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted this standard on January 1, 2026, and it did not have a material impact on the Company’s condensed consolidated financial statements or related disclosures.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update will improve disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, selling, general, and administrative expenses, and research and development). The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company will adopt the standard as of and for the year ending December 31, 2027 and for the interim reporting periods within the year ending December 31, 2028. This ASU will result in the required additional disclosures being included in the Company’s consolidated financial statements upon adoption. In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. This update will introduce changes to the timing of software cost capitalization based on likelihood of completion for all entities subject to the internal-use software guidance in Subtopic 350-40 and the guidance on website development costs in Subtopic 350-50. The ASU will be effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently evaluating the timing of adoption and the impact of adoption on its consolidated financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow Scope Improvements. This update will improve the navigability of required interim disclosures and clarify when that guidance is applicable, and will require entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The ASU is effective for interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company will adopt the standard for the interim periods within the year ending December 31, 2028. The Company is currently evaluating the impact of the adoption on its consolidated financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-12, Codification Improvements. This update will make a number of amendments to the Accounting Standards Codification and improvements to GAAP arising from technical corrections, unintended application of the Codification, clarifications, and other minor improvements. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods, with early adoption permitted in both interim and annual reporting periods for which financial statements have not yet been issued or made available for issuance. Entities may elect to early adopt the amendments on an issue-by-issue basis. The Company is currently evaluating the timing of adoption and the impact of adoption on its consolidated financial statements and related disclosures.

Stockholders' Equity	9 Months Ended
Sep. 30, 2026
Stockholders' Equity Note [Abstract]
Stockholders' Equity	7. STOCKHOLDERS’ EQUITY As of September 30, 2026 and December 31, 2025, the Company’s amended and restated certificate of incorporation authorized the Company to issue 500,000,000 shares of Class A common stock and 14,600,000 shares of Class B common stock, and 10,000,000 shares of preferred stock, each with a par value of $0.001 per share. Each share of Class A common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. There were no shares of Class B common stock or preferred stock outstanding as of September 30, 2026 and December 31, 2025. Common stockholders are entitled to receive dividends, as may be declared by the board of directors. Through September 30, 2026, no cash dividends have been declared or paid. In December 2025, the Company completed a follow-on public offering pursuant to which the Company issued and sold 7,058,824 shares of its Class A common stock at a public offering of $42.50 per share, including 920,716 shares of Class A common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares. Net proceeds from this follow-on public offering were $281.3 million, after deducting underwriting fees and offering-related expenses.

Stockholders' Equity

9 Months Ended

Sep. 30, 2026

Stockholders' Equity Note [Abstract]

Stockholders' Equity

7. STOCKHOLDERS’ EQUITY

As of September 30, 2026 and December 31, 2025, the Company’s amended and restated certificate of incorporation authorized the Company to issue 500,000,000 shares of Class A common stock and 14,600,000 shares of Class B common stock, and 10,000,000 shares of preferred stock, each with a par value of $0.001 per share. Each share of Class A common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. There were no shares of Class B common stock or preferred stock outstanding as of September 30, 2026 and December 31, 2025. Common stockholders are entitled to receive dividends, as may be declared by the board of directors. Through September 30, 2026, no cash dividends have been declared or paid.

In December 2025, the Company completed a follow-on public offering pursuant to which the Company issued and sold 7,058,824 shares of its Class A common stock at a public offering of $42.50 per share, including 920,716 shares of Class A common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares. Net proceeds from this follow-on public offering were $281.3 million, after deducting underwriting fees and offering-related expenses.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481520/505-30-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.D.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.B.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

Organization and Description of the Business - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2026 USD ($) Segment	Dec. 31, 2025 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments \| Segment	1
Accumulated deficit	$ (1,085,081)	$ (760,865)
Cash and cash equivalents and marketable securities	$ 384,000

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

+ Details

Stock Compensation (Tables)

9 Months Ended

Sep. 30, 2026

Share-Based Payment Arrangement [Abstract]

Summary of Company's Equity Plans

The table below summarizes the Company's equity plans as of September 30, 2026:


Plan	Maximum Number of Shares Authorized		Shares Available for Future Issuance
2024 Inducement Plan		4,390,000		558,695
2021 Equity Incentive Plan		13,614,767		3,927,855
2017 Equity Incentive Plan		2,275,305		—
2021 Employee Stock Purchase Plan		2,029,448		1,759,257

Summary of Share-based Compensation Arrangements by Share-based Payment Award

Stock option activity under the 2017 EIP, 2021 EIP, and 2024 Inducement Plan for the period ended September 30, 2026 is summarized as follows:


	Number of Options			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (000s)
Outstanding as of December 31, 2025		8,395,290		$	19.59		7.58	$	260,696
Granted		2,363,500		$	41.28
Exercised		(549,075	)	$	12.09
Cancelled and forfeited		(483,425	)	$	34.85
Outstanding as of September 30, 2026		9,726,290		$	24.52		7.48	$	103,868
Options exercisable as of September 30, 2026		5,282,414		$	17.57		6.48	$	84,344
Vested and expected to vest as of September 30, 2026		9,726,290		$	24.52		7.48	$	103,868

Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity

The following table shows RSU activity for the period ended September 30, 2026:


	Number of Shares			Weighted Average Grant Date Fair Value per Share
Unvested balance as of December 31, 2025		1,599,840		$	28.67
Granted		1,221,627			41.28
Vested		(351,299	)		27.40
Cancelled and forfeited		(224,403	)		33.43
Unvested balance as of September 30, 2026		2,245,765		$	35.25

Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount

The following tables summarize the stock-based compensation expense for stock options and restricted stock units granted to employees and non-employees and for ESPP stock-based compensation that was recorded in the Company’s condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026 and 2025 (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Research and development	$	6,768	$	4,533	$	20,174	$	12,286
Selling, general and administrative		8,960		5,212		24,625		14,675
Total stock-based compensation expense	$	15,728	$	9,745	$	44,799	$	26,961


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Employees	$	14,767	$	9,267	$	42,601	$	25,103
Non-employees		961		478		2,198		1,858
Total stock-based compensation expense	$	15,728	$	9,745	$	44,799	$	26,961

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The fair value of stock options granted during the three and nine months ended September 30, 2026 and 2025 was estimated using the Black-Scholes option pricing model based on the following assumptions:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Expected term (in years)	6.0 – 6.1	6.0 – 6.1	5.5 – 6.1	5.5 – 6.1
Expected volatility	79.6% – 80.9%	81.9% – 82.3%	78.1% – 87.6%	81.8% – 83.9%
Risk-free rate	4.3% – 5.1%	3.8% – 4.1%	3.7% – 5.1%	3.8% – 4.5%
Dividend yield	—	—	—	—

Cash, Cash Equivalents and Marketable Securities - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2026	Dec. 31, 2025
Cash Equivalents And Marketable Securities [Abstract]
Fair value of the debt securities	$ 328.7	$ 367.1

- Definition

Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (fff)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (ff)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 320
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477268/942-320-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-10

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-12

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 860
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (b)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 103
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-103

Reference 24: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481830/320-10-45-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1

+ Details

Segment Reporting

9 Months Ended

Sep. 30, 2026

Segment Reporting [Abstract]

Segment Reporting

12. SEGMENT REPORTING

The Company has one reportable segment: Therapeutics. This segment is dedicated to developing and commercializing medical treatments for patients with serious immunological diseases. The Company’s lead product, TRUTAKNA, was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression in July 2026. TRUTAKNA is a native human TACI-Fc fusion protein that binds both the B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) cytokines and is self-administered subcutaneously at home. Atacicept is also being evaluated for the treatment of other autoimmune kidney diseases and the Company intends to seek marketing approval of atacicept for the treatment of IgAN in regions outside of the U.S. in the future. The Company also holds worldwide, exclusive development and commercial rights to MAU868, a monoclonal antibody to treat reactivated BK virus infections, and worldwide, exclusive development and commercial rights to VT-109, a novel, next generation dual BAFF/APRIL inhibitor that is in preclinical development.

Since inception, the Company has devoted substantially all its resources to research and development efforts, pre-clinical studies and clinical trials, building a sales, marketing and distribution infrastructure to support commercial activities, establishing and maintaining intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.

The accounting policies used in the segment reporting are the same as those disclosed in the summary of significant accounting policies in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. The Company’s Chief Operating Decision Maker (CODM) is the Chief Executive Officer. The CODM assesses performance for the single reportable segment and

decides how to allocate resources based on net product revenue, cost of sales, total operating expenses, and net loss. The measure of segment assets is reported on the balance sheet as total assets.

The CODM uses net loss as the reportable segment’s primary measure of profit or loss to evaluate the segment’s financial position and to determine the need for additional financing or equity offerings.

The Company's reportable segment total operating expenses, including significant segment expenses, and net loss for the three and nine months ended September 30, 2026 and 2025, consisted of the following (in thousands):


	Therapeutics
	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Product revenue, net	$	10,277		$	—		$	10,277		$	—
Operating expenses:
Cost of sales		3,296			—			3,296			—
Payroll and related		47,380			29,240			137,964			75,189
Direct research and development - clinical trials		14,047			10,466			58,377			35,096
Direct research and development - contract drug manufacturing		6,631			21,909			52,828			54,949
Commercial expenses		14,458			5,716			37,498			12,485
Depreciation and amortization		243			129			515			333
Other segment items*		19,924			16,472			53,123			43,215
Total operating expenses		105,979			83,932			343,601			221,267
Loss from operations		(95,702	)		(83,932	)		(333,324	)		(221,267	)
Other income (expense):
Interest income		4,336			5,736			16,039			18,962
Interest expense		(1,873	)		(1,960	)		(5,544	)		(5,627	)
Other segment items**		(472	)		(137	)		(1,387	)		(586	)
Segment and consolidated net loss	$	(93,711	)	$	(80,293	)	$	(324,216	)	$	(208,518	)

*Other segment items included in total operating expenses primarily consist of consulting and contractors, professional services, equipment and software, travel and entertainment, facilities, medical affairs, and corporate communications.

**Other segment items included in net loss consist of currency exchange gains and losses and other income/expense.

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details

Notes Payable - Schedule of Notes Payable (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
Total borrowings	$ 75,000	$ 75,000
Accrued exit fees net of unamortized issuance costs	434	(162)
Net carrying amount of debt	$ 75,434	$ 74,838
SOFR [Member] \| Collateralized note 2025-06
Debt Instrument [Line Items]
Collateralized debt instrument maturity date	2030
Collateralized note, Effective interest rate	9.74%	9.85%
Collateralized note, Amount	$ 75,000	$ 75,000

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-6

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.9-06)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

+ Details

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

+ Details

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References + Details

Net Loss Per Share Attributable to Common Stockholders

9 Months Ended

Sep. 30, 2026

Earnings Per Share [Abstract]

Net Loss Per Share Attributable to Common Stockholders

10. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Class A common stock options issued and outstanding		9,726,290		8,408,580		9,726,290		8,408,580
Unvested restricted stock units		2,245,765		1,511,420		2,245,765		1,511,420
Shares reserved for ESPP purchases		19,714		18,599		19,714		18,599
Total		11,991,769		9,938,599		11,991,769		9,938,599

Notes Payable (Tables)

9 Months Ended

Sep. 30, 2026

Debt Disclosure [Abstract]

Schedule of Notes Payable

Notes payable consist of the following (in thousands, except years and percentages):


		September 30, 2026			December 31, 2025
	Maturity	Effective Interest Rate	Amount		Effective Interest Rate	Amount
Collateralized note 2025-06	2030	9.74%	$	75,000	9.85%	$	75,000
Total borrowings				75,000			75,000
Accrued exit fees net of unamortized issuance costs				434			(162	)
Net carrying amount of debt			$	75,434		$	74,838

Schedule Principal Installments Due

As of September 30, 2026, principal installments due on the notes were as follows (in thousands):


2026 (remaining)	$	—
2027		—
2028		—
2029		34,091
2030		40,909
Total long-term debt	$	75,000

Licenses And Intangible Assets - Summary of Intangible Assets, Net (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2026	Dec. 31, 2025
Intangible Asset, Finite-Lived [Line Items]
Gross Carrying Amount	$ 20,953	$ 0
Accumulated Amortization	(454)	0
Net Carrying Amount	$ 20,499	0
Acquired intellectual property
Intangible Asset, Finite-Lived [Line Items]
Weighted-Average Remaining Life	14 years 8 months 12 days
Gross Carrying Amount	$ 20,000	0
Accumulated Amortization	(335)	0
Net Carrying Amount	$ 19,665	0
Acquired internal-use software
Intangible Asset, Finite-Lived [Line Items]
Weighted-Average Remaining Life	1 year 10 months 24 days
Gross Carrying Amount	$ 953	0
Accumulated Amortization	(119)	0
Net Carrying Amount	$ 834	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482558/350-40-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 24: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 26: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 27: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 28: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-29

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 30: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-20

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 33: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 34: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 35: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 36: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-1

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5

+ Details

Cash, Cash Equivalents and Marketable Securities

9 Months Ended

Sep. 30, 2026

Cash Equivalents And Marketable Securities [Abstract]

Cash, Cash Equivalents and Marketable Securities

4. CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

The Company’s cash equivalents and available-for-sale investment securities are classified within the fair value hierarchy as defined by authoritative guidance. Level 1 securities consist of highly liquid money market funds for which the carrying amount approximates the fair value of identical assets as quoted in the active markets. Level 2 securities, consisting of U.S. Treasuries, U.S. agency securities and corporate debt securities, are measured based on other observable inputs, including broker or dealer quotations or other valuations using observable market data. The Company’s debt securities are accounted for as available-for-sale securities.

Unrealized gains and losses are reported as a component of other comprehensive income (loss). Fair value of the debt securities was $328.7 million and $367.1 million as of September 30, 2026 and December 31, 2025, respectively.

The following table presents the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):


	September 30, 2026
	Fair Value Hierarchy Level	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Money market funds	Level 1	$	47,026	$	—	$	—		$	47,026	$	47,026	$	—
U.S. Government bonds	Level 2		127,629		—		(175	)		127,454		—		127,454
U.S. Government agency securities	Level 2		16,996		—		(172	)		16,824		—		16,824
Corporate debt securities	Level 2		184,799		8		(365	)		184,442		—		184,442
Total cash equivalents and marketable securities			376,450		8		(712	)		375,746		47,026		328,720
Cash			8,296		—		—			8,296		8,296		—
Total		$	384,746	$	8	$	(712	)	$	384,042	$	55,322	$	328,720


	December 31, 2025
	Fair Value Hierarchy Level	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Money market funds	Level 1	$	342,915	$	—	$	—		$	342,915	$	342,915	$	—
U.S. Government bonds	Level 2		166,736		480		—			167,216		—		167,216
U.S. Government agency securities	Level 2		9,997		1		(23	)		9,975		—		9,975
Corporate debt securities	Level 2		189,536		329		(1	)		189,864		7,191		182,673
Total cash equivalents and marketable securities			709,184		810		(24	)		709,970		350,106		359,864
Cash			4,619		—		—			4,619		4,619		—
Total		$	713,803	$	810	$	(24	)	$	714,589	$	354,725	$	359,864

Marketable debt securities that had been in unrealized loss positions as of September 30, 2026, and December 31, 2025 were in an unrealized loss position for less than 12 months. Unrealized losses from marketable debt securities are primarily attributable to changes in interest rates and not due to credit-related factors. Management does not believe any remaining unrealized losses represent impairments or credit-related losses based on evaluation of available evidence.

The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates (in thousands):


	September 30, 2026
Due within one year	$	306,929
Due after one year to two years		21,791
Total marketable securities	$	328,720

Condensed Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Common Class A [Member] Common Stock [Member]
Beginning balances, shares at Dec. 31, 2024					63,559,858
Beginning Balances, Value at Dec. 31, 2024	$ 577,155	$ 1,037,948	$ 393	$ (461,250)	$ 64
Issuance of common stock pursuant to exercise of options, value	982	982
Issuance of common stock pursuant to exercise of options					100,587
Issuance of common stock upon vesting of restricted stock units, shares					90,283
Issuance of common stock pursuant to employee stock purchase plan					23,430
Issuance of common stock pursuant to employee stock purchase plan, value	551	551
Stock-based compensation	7,744	7,744
Change in unrealized gains and losses on marketable securities	261		261
Net loss	(51,694)			(51,694)
Ending Balances, shares at Mar. 31, 2025					63,774,158
Ending Balances, Value at Mar. 31, 2025	534,999	1,047,225	654	(512,944)	$ 64
Beginning balances, shares at Dec. 31, 2024					63,559,858
Beginning Balances, Value at Dec. 31, 2024	577,155	1,037,948	393	(461,250)	$ 64
Net loss	(208,518)
Ending Balances, shares at Sep. 30, 2025					63,894,845
Ending Balances, Value at Sep. 30, 2025	398,880	1,067,703	881	(669,768)	$ 64
Beginning balances, shares at Mar. 31, 2025					63,774,158
Beginning Balances, Value at Mar. 31, 2025	534,999	1,047,225	654	(512,944)	$ 64
Issuance of common stock pursuant to exercise of options, value	464	464
Issuance of common stock pursuant to exercise of options					45,162
Issuance of common stock upon vesting of restricted stock units, shares					4,345
Stock-based compensation	9,472	9,472
Change in unrealized gains and losses on marketable securities	(127)		(127)
Net loss	(76,531)			(76,531)
Ending Balances, shares at Jun. 30, 2025					63,823,665
Ending Balances, Value at Jun. 30, 2025	468,277	1,057,161	527	(589,475)	$ 64
Issuance of common stock pursuant to exercise of options, value	31	31
Issuance of common stock pursuant to exercise of options					4,882
Issuance of common stock upon vesting of restricted stock units, shares					28,390
Issuance of common stock pursuant to employee stock purchase plan					37,908
Issuance of common stock pursuant to employee stock purchase plan, value	766	766
Stock-based compensation	9,745	9,745
Change in unrealized gains and losses on marketable securities	354		354
Net loss	(80,293)			(80,293)
Ending Balances, shares at Sep. 30, 2025					63,894,845
Ending Balances, Value at Sep. 30, 2025	398,880	1,067,703	881	(669,768)	$ 64
Beginning balances, shares at Dec. 31, 2025					71,267,429
Beginning Balances, Value at Dec. 31, 2025	604,521	1,364,529	786	(760,865)	$ 71
Issuance of common stock pursuant to exercise of options, value	2,501	2,500			$ 1
Issuance of common stock pursuant to exercise of options					155,639
Issuance of common stock upon vesting of restricted stock units, shares					237,070
Issuance of common stock pursuant to employee stock purchase plan					69,952
Issuance of common stock pursuant to employee stock purchase plan, value	1,441	1,441
Stock-based compensation	13,208	13,208
Change in unrealized gains and losses on marketable securities	(942)		(942)
Net loss	(121,032)			(121,032)
Ending Balances, shares at Mar. 31, 2026					71,730,090
Ending Balances, Value at Mar. 31, 2026	499,697	1,381,678	(156)	(881,897)	$ 72
Beginning balances, shares at Dec. 31, 2025					71,267,429
Beginning Balances, Value at Dec. 31, 2025	604,521	1,364,529	786	(760,865)	$ 71
Net loss	(324,216)
Ending Balances, shares at Sep. 30, 2026					72,287,904
Ending Balances, Value at Sep. 30, 2026	333,186	1,418,899	(704)	(1,085,081)	$ 72
Beginning balances, shares at Mar. 31, 2026					71,730,090
Beginning Balances, Value at Mar. 31, 2026	499,697	1,381,678	(156)	(881,897)	$ 72
Issuance of common stock pursuant to exercise of options, value	1,918	1,918
Issuance of common stock pursuant to exercise of options					166,995
Issuance of common stock upon vesting of restricted stock units, shares					58,800
Stock-based compensation	15,863	15,863
Change in unrealized gains and losses on marketable securities	(247)		(247)
Net loss	(109,473)			(109,473)
Ending Balances, shares at Jun. 30, 2026					71,955,885
Ending Balances, Value at Jun. 30, 2026	407,758	1,399,459	(403)	(991,370)	$ 72
Issuance of common stock pursuant to exercise of options, value	2,218	2,218
Issuance of common stock pursuant to exercise of options					226,441
Issuance of common stock upon vesting of restricted stock units, shares					55,429
Issuance of common stock pursuant to employee stock purchase plan					50,149
Issuance of common stock pursuant to employee stock purchase plan, value	1,494	1,494
Stock-based compensation	15,728	15,728
Change in unrealized gains and losses on marketable securities	(301)		(301)
Net loss	(93,711)			(93,711)
Ending Balances, shares at Sep. 30, 2026					72,287,904
Ending Balances, Value at Sep. 30, 2026	$ 333,186	$ 1,418,899	$ (704)	$ (1,085,081)	$ 72

Cash, Cash Equivalents and Marketable Securities - Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Marketable Securities [Line Items]
Amortized Cost	$ 384,746	$ 713,803
Unrealized Gains	8	810
Unrealized Losses	(712)	(24)
Estimated Fair Value	384,042	714,589
Cash and Cash Equivalents	55,322	354,725
Marketable Securities	328,720	359,864
Cash Equivalents And Marketable Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	376,450	709,184
Unrealized Gains	8	810
Unrealized Losses	(712)	(24)
Estimated Fair Value	375,746	709,970
Cash and Cash Equivalents	47,026	350,106
Marketable Securities	328,720	359,864
Money Market Funds [Member] \| Level 1
Marketable Securities [Line Items]
Amortized Cost	47,026	342,915
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	47,026	342,915
Cash and Cash Equivalents	47,026	342,915
Marketable Securities	0	0
U.S. Government Bonds [Member] \| Level 2
Marketable Securities [Line Items]
Amortized Cost	127,629	166,736
Unrealized Gains	0	480
Unrealized Losses	(175)	0
Estimated Fair Value	127,454	167,216
Cash and Cash Equivalents	0	0
Marketable Securities	127,454	167,216
U.S. Government Agency Securities [Member] \| Level 2
Marketable Securities [Line Items]
Amortized Cost	16,996	9,997
Unrealized Gains	0	1
Unrealized Losses	(172)	(23)
Estimated Fair Value	16,824	9,975
Cash and Cash Equivalents	0	0
Marketable Securities	16,824	9,975
Corporate Debt Securities [Member] \| Level 2
Marketable Securities [Line Items]
Amortized Cost	184,799	189,536
Unrealized Gains	8	329
Unrealized Losses	(365)	(1)
Estimated Fair Value	184,442	189,864
Cash and Cash Equivalents	0	7,191
Marketable Securities	184,442	182,673
Cash [Member]
Marketable Securities [Line Items]
Amortized Cost	8,296	4,619
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	8,296	4,619
Cash and Cash Equivalents	8,296	4,619
Marketable Securities	$ 0	$ 0

Stock Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 29, 2024	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement by share based payment award, Options exercised in period, Total intrinsic value		$ 6,400	$ 100	$ 15,100	$ 3,800
Stock-based compensation expense		$ 15,728	$ 9,745	$ 44,799	$ 26,961
2021 and 2017 Amended Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period				10 years
2017 EIP, 2021 EIP and 2024 Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation arrangement by share based payment award, Options granted in period, Weighted average grant date fair value		$ 29.58	$ 18.31	$ 32.34	$ 22.56
Two Thousand And Twenty Four Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period	10 years
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares issued pursuant to ESPP		270,191		270,191
Stock-based compensation expense		$ 300	$ 100	$ 1,000	$ 400
Restricted Stock Units R S U [Member] \| 2021 and 2017 Amended Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, Nonvested awards, Compensation cost not yet recognized Stock options and equity instruments other than options		67,000		$ 67,000
Share based compensation, Nonvested awards, Compensation cost not yet recognized period of recognition stock options and equity instruments other than options				3 years
Stock-based compensation expense		4,800	2,700	$ 13,900	6,800
Employee Stock Option [Member] \| 2021 and 2017 Amended Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, Nonvested awards, Compensation cost not yet recognized Stock options and equity instruments other than options		98,700		$ 98,700
Share based compensation, Nonvested awards, Compensation cost not yet recognized period of recognition stock options and equity instruments other than options				2 years 7 months 6 days
Stock-based compensation expense		$ 10,600	$ 6,900	$ 29,800	$ 19,700

Stock Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected volatility, Minimum	79.60%	81.90%	78.10%	81.80%
Expected volatility, Maximum	80.90%	82.30%	87.60%	83.90%
Risk-free rate, Minimum	4.30%	3.80%	3.70%	3.80%
Risk-free rate, Maximum	5.10%	4.10%	5.10%	4.50%
Minimum [Member]
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)	6 years	6 years	5 years 6 months	5 years 6 months
Maximum [Member]
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days

Commitments and Contingencies

9 Months Ended

Sep. 30, 2026

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

9. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

The Company believes that there are no actions pending which would have a material adverse effect on its condensed consolidated financial statements.

Indemnification

As of September 30, 2026, the Company did not have any material indemnification claims that were probable and consequently no related liabilities have been recorded.

Employee Agreements

The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including severance and accelerated vesting of equity incentives.

Development and Manufacturing Services Agreements

The Company enters into development and manufacturing contracts with vendors in the conduct of its business. Contracts with these vendors may be terminated at the Company’s option, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would be obligated to pay for the products or services that had been provided or received at the time the termination became effective and potentially additional compensation based upon the period of time remaining between the date of notice of cancellation and the scheduled manufacturing.

To support product needs for TRUTAKNA, the Company has entered into manufacturing agreements which require the Company to meet minimum purchase obligations within an 18-month and 16-month period, respectively. The total amount of

minimum purchase obligations with these vendors as of September 30, 2026 was $88.1 million. As of September 30, 2026, the timing of minimum purchase obligations with these vendors was as follows (in thousands):


2026 (remaining)	$	38,901
2027		49,236
Total minimum purchase obligations	$	88,137

In October 2026, the Company cancelled certain scheduled research and development manufacturing activities which will result in an estimated loss of up to $14.6 million. The Company expects to recognize the amount of the loss as research and development expenses during the three months ending December 31, 2026.

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2026
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company and its subsidiary have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. The U.S. dollar is the Company’s functional and reporting currency. Principles of Consolidation In September 2026, the Company incorporated a wholly-owned, Netherlands-based subsidiary, Vera Therapeutics B.V., to help prepare for and assist with the Company’s activities in Europe. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. For the Company and its subsidiary, the functional currency has been determined to be in U.S. dollars. Unaudited Condensed Consolidated Financial Statements In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the periods presented. Interim results are not necessarily indicative of results for a full year or any other period. The information included in this Form 10-Q should be read in conjunction with the audited financial statements and related notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026. Use of Estimates The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the accrual of research and development expenses, valuation of equity awards for stock-based compensation, determination of incremental borrowing rate for operating leases, the valuation allowance for deferred tax assets, fair value of marketable securities, gross-to-net reserves for revenue recognition, and inventory valuation. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ from those estimates. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation, with no impact on previously reported net loss or total assets. Concentrations of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by any of the financial institutions holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations. For the three months ended September 30, 2026, two individual customers accounted for 94% of total gross product revenue, with these individual customers representing 76% and 18% of the Company’s total gross product revenue. As of September 30, 2026, two individual customers accounted for 94% of the gross accounts receivable balance, with these individual customers representing 76% and 18% of the gross accounts receivable balance. No other individual customers account for more than 10% of net product sales or accounts receivable. The Company monitors the financial condition of its customers so that it can appropriately respond to changes in their creditworthiness. To date, the Company has not experienced any losses with respect to the collection of its accounts receivable. The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s lead product or product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on single-source suppliers for some components of its supply chain. If any of the single source suppliers fails to satisfy the Company’s requirements on a timely basis, it could suffer delays in its clinical development programs and commercial launch activities, which could adversely affect operating results. TRUTAKNA is the Company’s only FDA-approved product and the success of its business depends, in part, on successful commercialization. In addition, the Company’s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any approved product, it could have a materially adverse impact on the Company. Accounts Receivable, Net Accounts receivable consists of trade receivables which are amounts due from the Company’s specialty pharmacy and specialty distributor customers related to product sales. The Company records trade receivables net of discounts, chargebacks, and any allowances for potential credit losses. Trade receivables are stated at their net realizable value. The Company estimates the allowance for credit losses using the current expected credit loss model. Under this model, the allowance for credit losses reflects the Company’s estimate of lifetime expected credit losses. The Company evaluates the collectability of the cash flows based on the risk of loss over the contractual life, even when that risk is remote, based on judgments about the creditworthiness of its customers, historical experience, and other relevant information that is available to the Company. The Company writes off trade receivables and related allowances for credit losses when it becomes probable it will not collect the amount receivable. For the three months ended September 30, 2026, the Company did not record any expected losses related to outstanding accounts receivable. There was no allowance for credit losses as of September 30, 2026. Inventory The Company began capitalizing inventory for TRUTAKNA upon approval by the FDA in July 2026 once commercialization was considered probable and the future economic benefit was expected to be realized. Prior to regulatory approval, all direct and indirect manufacturing costs for pre-launch inventory were charged to research and development expense in the periods incurred. Any eventual sale of previously expensed (“zero-cost”) inventories may impact future gross margins for any periods in which those inventories are sold. Inventory is comprised of raw materials, work-in-process and finished goods, and includes costs related to raw materials purchases, third-party contract manufacturing, shipping and handling, and product storage. The Company values inventory at the lower of cost or net realizable value and determines the cost of inventory using the specific identification method, which approximates a first-in, first-out basis. Certain raw materials and work-in-process inventory may be used in the manufacture of product for either research and development activities or commercial sale. Costs related to such inventory are initially capitalized as inventory and are expensed to research and development expense once a determination is made that product is to be used in research and development activities. The Company analyzes its inventory levels periodically for obsolescence and, if required, adjusts inventory to its net realizable value if the cost basis of inventory is in excess of its expected net realizable value, or for quantities in excess of expected demand. If the Company determines cost exceeds its net realizable value, the resulting adjustments are recognized as cost of sales in the Company’s Consolidated Statements of Operations and Comprehensive Loss. Intangible Assets, Net Finite-lived intangibles consist of contractual payments made in conjunction with license agreements for acquired intellectual property. The contractual payments are recorded as intangible assets at cost, net of accumulated amortization, and are amortized over their estimated useful life of the underlying intellectual property using the economic consumption method if anticipated future revenue can be reasonably estimated. The straight-line method is used when revenue cannot be reasonably estimated. Amortization of finite-lived intangibles is recorded in cost of sales in the Company’s Consolidated Statements of Operations and Comprehensive Loss. The economic consumption method is based on revenue generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenue of the Company’s marketed products is performed annually during the Company’s long-range planning cycle and whenever events or changes in circumstances would significantly affect anticipated lifetime revenue of the relevant products. The Company reviews its finite-lived intangible assets at least annually and when events or circumstances may indicate that the carrying value of these assets is not recoverable and exceeds their fair value. The Company measures fair value based on the estimated future undiscounted cash flows associated with these assets in addition to other assumptions and projections that the Company deems to be reasonable and supportable. If it is determined that an intangible asset becomes impaired, the carrying value is written down to its fair value with the related impairment charge recognized in the Company’s Consolidated Statements of Operations and Comprehensive Loss in the period in which the impairment occurs. The Company has not recorded any impairments of intangible assets to date. Product Revenue, Net The Company recognizes net product revenue from TRUTAKNA, which it began selling in the United States in July 2026 through contractual arrangements with its specialty pharmacy and specialty distributor customers. These customers subsequently resell the Company’s products to patients and certain medical centers or hospitals. In addition to distribution agreements with these customers, the Company enters into arrangements with governmental and contractual payors that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes net product revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (ASC 606), which outlines a five-step process for recognizing revenue from contracts with customers: (i) identify the contract with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the separate performance obligations in the contract, and (v) recognize revenue associated with the performance obligations as they are satisfied. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. The Company has determined that the delivery of TRUTAKNA to its customers constitutes a single performance obligation. There are no other promises to deliver goods or services beyond what is specified in each accepted customer order. The Company recognizes revenue from product sales when a customer obtains control of the Company’s product, which occurs at a point in time upon delivery of the product to the customer. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with the Company’s customers do not exceed one year and therefore the Company has elected to apply the practical expedient and no amount of consideration has been allocated as a financing component. Revenue from product sales is recorded at the net sales price (transaction price), which includes deductions based on estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company's sale of its products. These reserves, as detailed below, are based on the related sales, and are classified as reductions of accounts receivable, net, when the right of offset exists in accordance with ASU 2013-1, Balance Sheet (Topic 210): Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities, or as a current liability. These estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts. These estimates are based on limited historical experience and may rely on expected payer mix, contractual terms, and peer company analysis. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company's analysis also contemplated application of the constraint in accordance with the guidance, under which it determined a significant reversal of revenue would not occur in a future period and the transaction price will not be reduced further. Actual amounts of consideration ultimately received may differ from the Company's estimates. The Company will disclose significant judgments and estimates to variable consideration and timing of revenue recognition. If actual results in the future vary from the Company's estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances — The Company generally provides customers with discounts, which include incentive fees that are explicitly stated in the Company's contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The reserve for discounts is established in the same period that the related revenue is recognized, together with reductions to accounts receivable, net, on the balance sheets. Distribution Fees — The Company pays fees to our specialty distributor customers for distribution services provided in connection with the sales of TRUTAKNA. These specialty distributor fees are based on a contractually determined fixed percentage of sales. These payments are recorded as a reduction of revenue within the same period the related revenue is recognized. Product Returns — Consistent with industry practice, the Company offers its customers limited product return rights for damaged and expiring product, provided it is within a specified period around the product expiration date set forth in the applicable individual distribution agreement. The Company estimates the amount of product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as a reduction to accounts receivable, net on the balance sheets. The Company estimates product returns using its own sales information, including its visibility into the inventory remaining in the distribution channel. Chargebacks and Discounts — Chargebacks for fees and discounts to a third party represent the estimated obligations resulting from contractual commitments to sell products to contracted third parties at prices lower than the list prices charged to its customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the contracted third parties. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and a reduction to accounts receivable, net, on the balance sheets. Chargeback amounts are generally determined at the time of resale to the contracted third party by customers, and the Company generally issues credits for such amounts within a few days after the customer's notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to contracted third parties and chargebacks that customers have been claimed, but for which the Company has not yet issued a payment. Government Rebates — The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which will be included in accrued expenses on the balance sheets. The Company's liability for these rebates will consist of invoices received for claims from prior periods that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period. Commercial Rebates — The Company calculates the rebates it incurs according to any contracts with certain commercial payors and deducts these amounts from its gross product sales at the time revenues are recognized. Allowances (accrued) for commercial rebates are based on historical payments to payors from which is reasonably estimated at the time of delivery. Rebates are recorded as accrued expenses in the balance sheet. Co-pay Assistance — Other incentives the Company offers include voluntary patient assistance programs, such as the co-pay assistance program, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors. The calculation of monthly co-pay assistance will be based on an estimated number of claims for the period and the estimated cost per claim associated with product that has been recognized as revenue. Cost of Sales Cost of sales includes the cost of inventory sold, indirect labor costs, product shipping costs, amortization expense of finite-lived intangible assets associated with acquired intellectual property, and third-party royalties payable on the Company’s net product revenue. Cost of sales may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, and manufacturing variances. Prior to regulatory approval, all direct and indirect manufacturing costs for pre-launch inventory of TRUTAKNA were charged to research and development expense in the periods incurred. As a result, the cost basis of inventory available for sale at the time of approval was zero, and cost of sales is correspondingly low during the initial period following launch. Following FDA approval, the Company capitalizes direct manufacturing costs as inventory and recognizes these amounts in cost of sales when the related inventory is sold. Accordingly, cost of sales for the period may not be indicative of the full cost of units sold, and cost of sales and gross margin during the initial periods following commercialization may not be representative of future periods as the Company begins capitalizing and expensing post-approval manufacturing costs. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. Recently Adopted Accounting Pronouncements In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This update will provide all entities with a practical expedient in developing reasonable and supportable forecasts as part of estimating expected credit losses by assuming that current conditions as of the balance sheet date do not change for the remaining life of the asset. The ASU is effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company adopted this standard on January 1, 2026, and it did not have a material impact on the Company’s condensed consolidated financial statements or related disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update will improve disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, selling, general, and administrative expenses, and research and development). The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company will adopt the standard as of and for the year ending December 31, 2027 and for the interim reporting periods within the year ending December 31, 2028. This ASU will result in the required additional disclosures being included in the Company’s consolidated financial statements upon adoption. In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. This update will introduce changes to the timing of software cost capitalization based on likelihood of completion for all entities subject to the internal-use software guidance in Subtopic 350-40 and the guidance on website development costs in Subtopic 350-50. The ASU will be effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods, with early adoption permitted as of the beginning of an annual reporting period. The Company is currently evaluating the timing of adoption and the impact of adoption on its consolidated financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow Scope Improvements. This update will improve the navigability of required interim disclosures and clarify when that guidance is applicable, and will require entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The ASU is effective for interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. The Company will adopt the standard for the interim periods within the year ending December 31, 2028. The Company is currently evaluating the impact of the adoption on its consolidated financial statements and related disclosures. In December 2025, the FASB issued ASU 2025-12, Codification Improvements. This update will make a number of amendments to the Accounting Standards Codification and improvements to GAAP arising from technical corrections, unintended application of the Codification, clarifications, and other minor improvements. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods, with early adoption permitted in both interim and annual reporting periods for which financial statements have not yet been issued or made available for issuance. Entities may elect to early adopt the amendments on an issue-by-issue basis. The Company is currently evaluating the timing of adoption and the impact of adoption on its consolidated financial statements and related disclosures.

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Cash flows from operating activities
Net loss	$ (324,216)	$ (208,518)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,095	333
Accretion of discount and amortization of premium on purchase of debt securities	(2,995)	(5,872)
Accretion of loan exit fee and amortization of loan costs	1,939	1,220
Reduction in the carrying amount of operating lease right-of-use assets	360	1,336
Stock-based compensation	44,799	26,961
Upfront and milestone obligations under license agreements	15,000	800
Changes in operating assets and liabilities:
Accounts receivable	(11,981)	0
Inventory	(7,078)	0
Prepaid expense and other current assets	(24,353)	(3,506)
Accounts payable	(1,702)	10,285
Accrued and other liabilities	3,576	7,234
Operating lease liabilities	(373)	(1,383)
Net cash used in operating activities	(305,929)	(171,110)
Cash flows from investing activities
Upfront and milestone payments under license agreements	(35,000)	(800)
Purchase of internal use software license	(673)	0
Purchase of property and equipment	(23)	(528)
Purchase of marketable securities	(357,125)	(285,947)
Proceeds from maturities of marketable securities	389,775	400,897
Net cash provided by (used in) investing activities	(3,046)	113,622
Cash flows from financing activities
Proceeds from exercise of stock options and employee stock purchase plan	9,572	2,794
Proceeds from refinancing under loan and security agreement, net	0	23,338
Payment of deferred issuance costs related to unfunded loan commitments	0	(3,517)
Net cash provided by financing activities	9,572	22,615
Net decrease in cash and cash equivalents	(299,403)	(34,873)
Cash and cash equivalents, beginning of period	354,725	92,646
Cash and cash equivalents, end of period	55,322	57,773
Supplemental disclosure of cash flow information
Cash paid for interest expense	4,948	5,004
Internal-use software license acquired through accrued liabilities	$ 280	$ 0

Other Financial Statement Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Other Financial Statement Information [Abstract]
Raw materials	$ 5,799	$ 0
Work in process	929	0
Finished goods	350	0
Total inventory	$ 7,078	$ 0

Notes Payable - Schedule Principal Installments Due (Details) $ in Thousands	Sep. 30, 2026 USD ($)
Debt Disclosure [Abstract]
2026 (remaining)	$ 0
2027	0
2028	0
2029	34,091
2030	40,909
Total long-term debt	$ 75,000

Other Financial Statement Information - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 31, 2026	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Inventory [Line Items]
Research and Development Expense		$ 41,253	$ 56,473	$ 187,344	$ 155,946
TRUTAKNA [Member]
Inventory [Line Items]
Research and Development Expense	$ 29,100
Sale of prelaunch inventory costs		400		400
Remaining Pre Launch Inventory Cost		$ 26,000		$ 26,000

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2026	Oct. 29, 2026
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2026
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q3
Trading Symbol	VERA
Entity Registrant Name	Vera Therapeutics, Inc.
Entity Central Index Key	0001831828
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Class A common stock, $0.001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-40407
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-2744449
Document Quarterly Report	true
Document Transition Report	false
Entity Address, Address Line One	2000 Sierra Point Parkway
Entity Address, Address Line Two	Suite 1200
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	650
Local Phone Number	770-0077
Entity Common Stock, Shares Outstanding		72,298,770

Notes Payable

9 Months Ended

Sep. 30, 2026

Debt Disclosure [Abstract]

Notes Payable

6. NOTES PAYABLE

Notes payable consist of the following (in thousands, except years and percentages):


		September 30, 2026			December 31, 2025
	Maturity	Effective Interest Rate	Amount		Effective Interest Rate	Amount
Collateralized note 2025-06	2030	9.74%	$	75,000	9.85%	$	75,000
Total borrowings				75,000			75,000
Accrued exit fees net of unamortized issuance costs				434			(162	)
Net carrying amount of debt			$	75,434		$	74,838

2021 Loan Agreement

In June 2025, the Company refinanced its debt under the non-revolving loan and security agreement (2021 Loan Agreement) with a loan syndicate involving Oxford Finance LLC (Oxford Finance), Oxford Finance Credit Fund II LP (OFCF II), and Oxford Finance Credit Fund III LP (OFCF III) entered into in December 2021, by entering into a new non-revolving loan and security agreement, the proceeds of which were partially used to prepay the outstanding principal balance of the 2021 Loan Agreement in full. The Company paid an exit fee of $3.0 million, equal to 6% on the aggregate principal amount of the loan, as 1% of the original 7% exit fee was waived in connection with the refinancing. The entirety of the 2% prepayment fee that would have applied to the prepayment of the $25.0 million of debt drawn in December 2023 was also waived in connection with the refinancing.

2025 Loan Agreement

In June 2025, the Company entered into a new non-revolving loan and security agreement (2025 Loan Agreement) with a loan syndicate involving Oxford Finance, OFCF II, OFCF III, and Oxford Finance Credit Fund IV LP (OFCF IV) (collectively, Oxford). The 2025 Loan Agreement has a total borrowing capacity of up to $500.0 million, of which $75.0 million was funded at closing and $50.0 million remains available for draw at the Company’s discretion until December 31, 2026. Following accelerated approval of TRUTAKNA by the FDA in July 2026, an additional $75.0 million became available for draw at the Company’s discretion. In October 2026, the Company elected to draw this tranche and received net cash proceeds of $74.0 million after deduction of fees and prepaid interest. The Company also has the option to draw two tranches, each of a maximum of $50.0 million, upon achievement of certain commercial milestones related to TRUTAKNA once approved, and up to $200.0 million available at the mutual discretion of the Company and Oxford. As of September 30, 2026, the Company’s outstanding borrowing under the 2025 Loan Agreement was $75.0 million.

The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transaction as a loan modification, and with respect to the new lender, OFCF IV, the Company accounted for this transaction as an issuance of debt. Of the $3.7 million in exit fees on the 2021 Loan Agreement and fees paid to creditors as part of the refinancing, $1.6 million was recorded as a reduction to the net carrying amount of the debt drawn under the 2025 Loan Agreement at close, and $2.0 million was recorded as noncurrent deferred debt issuance costs. Of the $2.3 million in fees paid by the Company to third parties in connection with the refinancing, $0.8 million was recorded as other expense, and $1.4 million was recorded as noncurrent deferred debt issuance costs. Deferred debt issuance costs will be amortized over the respective draw periods of each of the loan commitment tranches on a straight-line basis.

The 2025 Loan Agreement is scheduled to mature in June 2030, provided that the Company has not achieved a revenue-based interest-only extension milestone as of the end of the initial interest-only period in August 2029. If the Company achieves this interest-only extension milestone, the maturity date and end of the interest-only period will be extended to June 2031 and August 2030, respectively. The Company is permitted to prepay the loan, subject to certain conditions, and will incur prepayment fees of 2% if the loan is prepaid prior to June 4, 2027, or 1% if the loan is prepaid between June 5, 2027, and June 4, 2028. No prepayment fee shall be applicable after June 4, 2028. Additionally, upon maturity date, acceleration of the loan in the event of default, or prepayment of the loan, the Company is required to pay an exit fee equal to 5% of the aggregate principal amount of the loan. The Company will accrue for this exit fee over the life of the loan as an increase to the net carrying amount of debt using the effective interest rate method.

The variable interest rate on the drawn amount is 1-Month CME Term SOFR (subject to a per annum floor rate of 3.75%) plus 4.95% per annum. At the initial funding of the 2025 Loan Agreement on June 4, 2025, the nominal interest rate was 9.27%. There are two financial covenants: (i) commencing on March 31, 2027, the Company is required to maintain certain levels of unrestricted cash subject to control agreements provided that such liquidity covenant shall not apply at any given time if the market capitalization of the Company is at least $1.0 billion on the measurement date, and (ii) commencing with the last day of the month in which the aggregate amount of Term Loans funded exceeds $200.0 million, the Company will be required to maintain a loan coverage ratio, which will replace the minimum cash covenant. The loan coverage ratio should not apply at any given time if the market capitalization of the Company is at least $1.25 billion on the measurement date. The loan is secured by substantially all of the Company’s assets. The

proceeds from the 2025 Loan Agreement were partially used to prepay the outstanding principal balance of the 2021 Loan Agreement in full, with the remaining proceeds available for working capital, capital expenditures, and other general corporate purposes.

As of September 30, 2026, principal installments due on the notes were as follows (in thousands):


2026 (remaining)	$	—
2027		—
2028		—
2029		34,091
2030		40,909
Total long-term debt	$	75,000

Licenses And Intangible Assets - Summary of Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Licenses [Abstract]
2026 (remaining)	$ 444
2027	1,776
2028	1,631
2029	1,341
2030	1,341
Thereafter	13,966
Total estimated future amortization expense	$ 20,499	$ 0

Other Financial Statement Information - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Other Financial Statement Information [Abstract]
Accrued payroll	$ 15,036	$ 18,700
Accrued drug manufacturing costs	6,408	8,427
Accrued clinical trial costs	4,678	1,333
Accrued commercial planning, sales and marketing expenses	3,516	1,181
Sales discounts, rebates, and allowances	1,703	0
Accrued royalties	1,439	0
Other	2,822	1,916
Total accrued expenses and other current liabilities	$ 35,602	$ 31,557

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2026

Segment Reporting [Abstract]

Schedule of Segment Operating Expenses Including Segment Expenses, and Net Loss


	Therapeutics
	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Product revenue, net	$	10,277		$	—		$	10,277		$	—
Operating expenses:
Cost of sales		3,296			—			3,296			—
Payroll and related		47,380			29,240			137,964			75,189
Direct research and development - clinical trials		14,047			10,466			58,377			35,096
Direct research and development - contract drug manufacturing		6,631			21,909			52,828			54,949
Commercial expenses		14,458			5,716			37,498			12,485
Depreciation and amortization		243			129			515			333
Other segment items*		19,924			16,472			53,123			43,215
Total operating expenses		105,979			83,932			343,601			221,267
Loss from operations		(95,702	)		(83,932	)		(333,324	)		(221,267	)
Other income (expense):
Interest income		4,336			5,736			16,039			18,962
Interest expense		(1,873	)		(1,960	)		(5,544	)		(5,627	)
Other segment items**		(472	)		(137	)		(1,387	)		(586	)
Segment and consolidated net loss	$	(93,711	)	$	(80,293	)	$	(324,216	)	$	(208,518	)

**Other segment items included in net loss consist of currency exchange gains and losses and other income/expense.

Segment Reporting - Additional Information (Details)	9 Months Ended
Segment Reporting - Additional Information (Details)	Sep. 30, 2026 Segment
Segment Reporting [Abstract]
Number of reportable segments	1
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	srt:ChiefExecutiveOfficerMember
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description	The CODM uses net loss as the reportable segment’s primary measure of profit or loss to evaluate the segment’s financial position and to determine the need for additional financing or equity offerings.

Cash, Cash Equivalents and Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2026

Investments, Debt and Equity Securities [Abstract]

Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities

The following table presents the Company’s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):


	September 30, 2026
	Fair Value Hierarchy Level	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Money market funds	Level 1	$	47,026	$	—	$	—		$	47,026	$	47,026	$	—
U.S. Government bonds	Level 2		127,629		—		(175	)		127,454		—		127,454
U.S. Government agency securities	Level 2		16,996		—		(172	)		16,824		—		16,824
Corporate debt securities	Level 2		184,799		8		(365	)		184,442		—		184,442
Total cash equivalents and marketable securities			376,450		8		(712	)		375,746		47,026		328,720
Cash			8,296		—		—			8,296		8,296		—
Total		$	384,746	$	8	$	(712	)	$	384,042	$	55,322	$	328,720


	December 31, 2025
	Fair Value Hierarchy Level	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value		Cash and Cash Equivalents		Marketable Securities
Money market funds	Level 1	$	342,915	$	—	$	—		$	342,915	$	342,915	$	—
U.S. Government bonds	Level 2		166,736		480		—			167,216		—		167,216
U.S. Government agency securities	Level 2		9,997		1		(23	)		9,975		—		9,975
Corporate debt securities	Level 2		189,536		329		(1	)		189,864		7,191		182,673
Total cash equivalents and marketable securities			709,184		810		(24	)		709,970		350,106		359,864
Cash			4,619		—		—			4,619		4,619		—
Total		$	713,803	$	810	$	(24	)	$	714,589	$	354,725	$	359,864

Schedule of Estimated Fair Value of Investments in Available-for-sale Marketable Debt Securities

The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates (in thousands):


	September 30, 2026
Due within one year	$	306,929
Due after one year to two years		21,791
Total marketable securities	$	328,720

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

+ Details

Basis of Presentation and Significant Accounting Policies - Additional Information (Details) - Customer Concentration Risk [Member]	3 Months Ended	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2026
Accounts Receivable [Member] \| Two Individual Customers [Member]
Product Information [Line Items]
Concentration Risk, Percentage		94.00%
Accounts Receivable [Member] \| Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage		76.00%
Accounts Receivable [Member] \| Customer Two [Member]
Product Information [Line Items]
Concentration Risk, Percentage		18.00%
Accounts Receivable [Member] \| No Other Individual Customers [Member]
Product Information [Line Items]
Concentration Risk, Percentage		10.00%
Revenue Benchmark [Member] \| Two Individual Customers [Member]
Product Information [Line Items]
Concentration Risk, Percentage	94.00%
Revenue Benchmark [Member] \| Customer One [Member]
Product Information [Line Items]
Concentration Risk, Percentage	76.00%
Revenue Benchmark [Member] \| Customer Two [Member]
Product Information [Line Items]
Concentration Risk, Percentage	18.00%

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References + Details

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	Oct. 31, 2026	Sep. 30, 2026
Loss Contingencies [Line Items]
Total minimum purchase obligations		$ 88.1
Subsequent Event [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Estimated loss	$ 14.6

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482645/405-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.W.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

+ Details

- Definition

Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.Z.5.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480781/205-20-S99-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480868/205-20-S45-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-2

+ Details

Licenses And Intangible Assets - Additional Information (Details) - USD ($) $ in Millions		1 Months Ended	9 Months Ended
	Sep. 30, 2026	Jan. 31, 2026	Sep. 30, 2026	Aug. 31, 2026
Intellectual Property [Member]
Repurchase Agreement Counterparty [Line Items]
Intangible asset amortization expense			$ 0.3
Software, Internally Developed [Member]
Repurchase Agreement Counterparty [Line Items]
Intangible asset amortization expense			0.1
Ares Trading S A [Member] \| Ares Agreement [Member]
Repurchase Agreement Counterparty [Line Items]
Milestone payments paid		$ 15.0
Milestone payments payable				$ 20.0
Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member] \| Ares Trading S A [Member] \| Ares Agreement [Member]
Repurchase Agreement Counterparty [Line Items]
Milestone payments payable	$ 131.5		131.5
Regulatory Approval In The U S [Member] \| Ares Trading S A [Member] \| Ares Agreement [Member]
Repurchase Agreement Counterparty [Line Items]
Milestone payments payable	10.0		10.0
Achievement of Specified Worldwide Aggregate Annual Net Sales Milestones Reach Two Fifty Million [Member] \| Ares Trading S A [Member] \| Ares Agreement [Member]
Repurchase Agreement Counterparty [Line Items]
Milestone payments payable	15.0		15.0
License agreement	250.0
Achievement of Specified Worldwide Aggregate Annual Net Sales Milestones Reach Five Hundred Million [Member] \| Ares Trading S A [Member] \| Ares Agreement [Member]
Repurchase Agreement Counterparty [Line Items]
Milestone payments payable	50.0		50.0
License agreement	500.0
Maximum [Member] \| Achievement of Specified Worldwide Aggregate Annual Net Sales Milestones [Member] \| Ares Trading S A [Member] \| Ares Agreement [Member]
Repurchase Agreement Counterparty [Line Items]
Milestone payments payable	$ 515.0		$ 515.0

Commitments and Contingencies - Schedule of Minimum Purchase Obligations (Details) $ in Thousands	Sep. 30, 2026 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2026 (remaining)	$ 38,901
2027	49,236
Total minimum purchase obligations	$ 88,137

Cash, Cash Equivalents And Marketable Securities - Schedule of Estimated Fair Value of Marketable Securities by Stated Contractual Maturities (Details) $ in Thousands	Sep. 30, 2026 USD ($)
Cash Equivalents And Marketable Securities [Abstract]
Due within one year	$ 306,929
Due after one year to two years	21,791
Total marketable securities	$ 328,720

Notes Payable - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended
	Jun. 02, 2025	Oct. 31, 2026	Sep. 30, 2026	Jul. 07, 2026	Jun. 04, 2025
Debt Instrument [Line Items]
Carrying amount of debt outstanding			$ 75,000
2021 Loan Agreement [Member]
Debt Instrument [Line Items]
Exit fees, debt issuance costs	$ 3,000
Percentage of exit fee on old debt principal amount	6.00%
Percentage of old debt exit fee waived in connection with the refinancing	1.00%
Percentage of original contractual exit fee on old debt	7.00%
Percentage of prepayment fee	2.00%
2021 Loan Agreement [Member] \| Collateralized note 2023-12
Debt Instrument [Line Items]
Debt principal balance of collateralized note	$ 25,000
2025 Loan Agreement [Member]
Debt Instrument [Line Items]
Revolving credit facility with borrowing capacity	$ 500,000
Carrying amount of debt outstanding			$ 75,000
Line of credit exit fee percentage	5.00%
Debt issuance costs paid to creditors	$ 3,700
Reduction to the net carrying amount	1,600
Allocation to noncurrent deferred finance cost	2,000
Debt issuance costs paid to third parties	2,300
Debt Issuance costs paid to third parties allocated to other nonoperating expense	800
Debt issuance costs paid to noncurrent deferred financing costs	$ 1,400
Prepayment fee percentage first two years	2.00%
Prepayment fee percentage year three	1.00%
Nominal interest rate					9.27%
2025 Loan Agreement [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Market capitalization threshold amount invalidating liquidity covenant	$ 1,000,000
2025 Loan Agreement [Member] \| Base Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	3.75%
2025 Loan Agreement [Member] \| 1-Month CME Term SOFR [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	4.95%
2025 Loan Agreement [Member] \| Tranche A [Member]
Debt Instrument [Line Items]
Remaining capacity available	$ 50,000
Amount withdrawn from the loan agreement	75,000
2025 Loan Agreement [Member] \| Tranche B [Member] \| TRUTAKNA [Member]
Debt Instrument [Line Items]
Remaining capacity available				$ 75,000
2025 Loan Agreement [Member] \| Tranche B [Member] \| TRUTAKNA [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Net cash proceeds		$ 74,000
2025 Loan Agreement [Member] \| Tranche C [Member] \| TRUTAKNA [Member]
Debt Instrument [Line Items]
Amount of debt available on achievements on milestones	50,000
2025 Loan Agreement [Member] \| Tranche D [Member] \| TRUTAKNA [Member]
Debt Instrument [Line Items]
Amount of debt available on achievements on milestones	50,000
2025 Loan Agreement [Member] \| Tranche E [Member]
Debt Instrument [Line Items]
Maximum available capacity	200,000
2025 Loan Agreement [Member] \| Term Loan [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Debt instrument threshold amount invalidating liquidity covenant	200,000
Market capitalization threshold amount invalidating the loan coverage ratio	$ 1,250,000

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Revenue:
Product revenue, net	$ 10,277	$ 0	$ 10,277	$ 0
Operating expenses:
Cost of sales	3,296	0	3,296	0
Research and development	41,253	56,473	187,344	155,946
Selling, general and administrative	61,430	27,459	152,961	65,321
Total operating expenses	105,979	83,932	343,601	221,267
Loss from operations	(95,702)	(83,932)	(333,324)	(221,267)
Other income (expense):
Interest income	4,336	5,736	16,039	18,962
Interest expense	(1,873)	(1,960)	(5,544)	(5,627)
Other expense, net	(472)	(137)	(1,387)	(586)
Total other income, net	1,991	3,639	9,108	12,749
Net loss	(93,711)	(80,293)	(324,216)	(208,518)
Other comprehensive loss:
Change in unrealized gains and losses on marketable securities	(301)	354	(1,490)	488
Comprehensive loss	$ (94,012)	$ (79,939)	$ (325,706)	$ (208,030)
Net loss per share attributable to common stockholders, basic	$ (1.3)	$ (1.26)	$ (4.51)	$ (3.27)
Net loss per share attributable to common stockholders, diluted	$ (1.3)	$ (1.26)	$ (4.51)	$ (3.27)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	72,126,588	63,847,055	71,816,111	63,769,948
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	72,126,588	63,847,055	71,816,111	63,769,948

Other Financial Statement Information

9 Months Ended

Sep. 30, 2026

Other Financial Statement Information [Abstract]

Other Financial Statement Information

3. OTHER FINANCIAL STATEMENT INFORMATION

Inventory

Inventory consists of the following (in thousands):


	September 30, 2026		December 31, 2025
Raw materials	$	5,799	$	—
Work in process		929		—
Finished goods		350		—
Total inventory	$	7,078	$	—

Prior to FDA approval of TRUTAKNA in July 2026, the Company expensed approximately $29.1 million in costs associated with the manufacturing of TRUTAKNA pre-launch inventory as a component of research and development expense. If these previously expensed costs had been capitalized as inventory and subsequently included as a component of cost of sales as pre-launch inventory was sold, the increase to cost of sales would have been approximately $0.4 million during the three and nine months ended September 30, 2026. As of September 30, 2026, the previously expensed cost of the remaining pre-launch inventory on hand was approximately $26.0 million, which includes inventory that could be used for either research and development or commercial purposes.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	September 30, 2026		December 31, 2025
Prepaid drug manufacturing costs	$	23,370	$	1,637
Prepaid clinical trial costs		2,969		3,435
Interest income receivable		2,586		3,285
Prepaid software costs		2,349		1,669
Other		6,910		4,268
Total prepaid expenses and other current assets	$	38,184	$	14,294

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):


	September 30, 2026		December 31, 2025
Accrued payroll	$	15,036	$	18,700
Accrued drug manufacturing costs		6,408		8,427
Accrued clinical trial costs		4,678		1,333
Accrued commercial planning, sales and marketing expenses		3,516		1,181
Sales discounts, rebates, and allowances		1,703		—
Accrued royalties		1,439		—
Other		2,822		1,916
Total accrued expenses and other current liabilities	$	35,602	$	31,557

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 55,322	$ 354,725
Marketable securities	328,720	359,864
Accounts receivable, net	11,981	0
Inventory	7,078	0
Prepaid expenses and other assets, current	38,184	14,294
Total current assets	441,285	728,883
Intangible assets, net	20,499	0
Other assets, noncurrent	3,968	5,850
Total assets	465,752	734,733
Current liabilities:
Accounts payable	20,173	21,898
Accrued expenses and other liabilities, current	35,602	31,557
Total current liabilities	55,775	53,455
Long-term debt	75,434	74,838
Other liabilities, noncurrent	1,357	1,919
Total liabilities	132,566	130,212
Stockholders' equity
Class A common stock, $0.001 par value; 500,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 72,287,904 and 71,267,429 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively	72	71
Additional paid-in capital	1,418,899	1,364,529
Accumulated other comprehensive (loss) income	(704)	786
Accumulated deficit	(1,085,081)	(760,865)
Total stockholders' equity	333,186	604,521
Total liabilities and stockholders' equity	$ 465,752	$ 734,733

Licenses And Intangible Assets

9 Months Ended

Sep. 30, 2026

Licenses [Abstract]

Licenses And Intangible Assets

5. LICENSES AND INTANGIBLE ASSETS

Ares Trading S.A. License Agreement (Ares Agreement)

The Company has a license agreement with Ares Trading S.A. (Ares), pursuant to which the Company maintains an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation.

In January 2026, the Company achieved a specified regulatory milestone and paid $15.0 million to Ares upon acceptance of the Company’s Biologics License Application (BLA) for TRUTAKNA for treatment of IgAN by the FDA. This was recorded as research and development expense. Upon accelerated approval of the Company’s BLA for TRUTAKNA for treatment of IgAN by the FDA in July 2026, the Company achieved a specified regulatory milestone and paid $20.0 million to Ares in August 2026. This milestone payment was capitalized as acquired intellectual property, and is being amortized to cost of sales over its estimated useful life.

The Company is obligated to pay Ares additional milestone payments, including $10.0 million upon the first filing of an approval application in the European Union, and other potential milestone payments of up to $131.5 million in aggregate upon the achievement of regulatory filing and approval milestones for other geographic regions and indications, and up to $515.0 million upon the achievement of specified worldwide aggregate annual net sales milestones, beginning with $15.0 million if net sales reach $250.0 million and $50.0 million if net sales reach $500.0 million.

Pursuant to the Ares Agreement, the Company is obligated to pay Ares tiered royalties of low double-digit to mid-teen percentages on worldwide aggregate annual net sales of atacicept, with payments due quarterly. The Company began incurring costs associated with such royalties following the July 2026 approval of TRUTAKNA (atacicept) and records these royalties within cost of sales. In the event the Company sublicenses its rights under the Ares Agreement, the Company would be obligated to pay Ares a percentage ranging from the mid-single-digits to the low double-digits of specified sublicensing income received.

Intangible Assets

Intangible assets, net consist of the following (in thousands, except years):


	September 30, 2026								December 31, 2025
	Weighted-Average Remaining Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted-Average Remaining Life	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Finite-lived intangible assets
Acquired intellectual property	14.7 years	$	20,000	$	(335	)	$	19,665	N/A	$	—	$	—	$	—
Acquired internal-use software	1.9 years		953		(119	)		834	N/A		—		—		—
Total		$	20,953	$	(454	)	$	20,499		$	—	$	—	$	—

The Company recorded intangible asset amortization expense of $0.3 million related to acquired intellectual property to cost of sales in the three and nine months ended September 30, 2026. The Company recorded intangible asset amortization expense of $0.1 million related to acquired internal-use software to selling, general and administrative expenses in the three and nine months ended September 30, 2026.

As of September 30, 2026, the estimated future amortization expense associated with the Company’s finite-lived intangible assets was as follows:


2026 (remaining)	$	444
2027		1,776
2028		1,631
2029		1,341
2030		1,341
Thereafter		13,966
Total estimated future amortization expense	$	20,499

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - Common Class A [Member] - $ / shares	Sep. 30, 2026	Dec. 31, 2025
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, Shares issued	72,287,904	71,267,429
Common stock, Shares outstanding	72,287,904	71,267,429

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Stock Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Details) - 2017 EIP, 2021 EIP and 2024 Inducement Plan [Member] $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2026 USD ($) $ / shares shares	Dec. 31, 2025 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Beginning \| shares	8,395,290
Number of Options, Granted \| shares	2,363,500
Number of Options, Exercised \| shares	(549,075)
Number of Options, Cancelled and forfeited \| shares	(483,425)
Number of Options, Ending \| shares	9,726,290	8,395,290
Number of Options, Options exercisable \| shares	5,282,414
Number of Options, Vested and expected to vest \| shares	9,726,290
Weighted-Average Exercise Price, Opening balance \| $ / shares	$ 19.59
Weighted Average Exercise Price, Granted \| $ / shares	41.28
Weighted Average Exercise Price, Exercised \| $ / shares	12.09
Weighted Average Exercise Price, Cancelled and forfeited \| $ / shares	34.85
Weighted Average Exercise Price, Ending balance \| $ / shares	24.52	$ 19.59
Weighted Average Exercise Price, Option exercisable \| $ / shares	17.57
Weighted Average Exercise Price, Vested and expected to vest \| $ / shares	$ 24.52
Weighted-Average Remaining Contractual Life	7 years 5 months 23 days	7 years 6 months 29 days
Weighted Average Remaining Contractual Life, Options exercisable	6 years 5 months 23 days
Weighted Average Remaining Contractual Life, Vested and expected to vest	7 years 5 months 23 days
Aggregate Intrinsic Value, Outstanding \| $	$ 103,868	$ 260,696
Aggregate Intrinsic Value, Options exercisable \| $	84,344
Aggregate Intrinsic Value, Vested and expected to vest \| $	$ 103,868

Organization and Description of the Business

9 Months Ended

Sep. 30, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Description of the Business

1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS

Description of Business

Vera Therapeutics, Inc. (the Company) is a commercial-stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware. The Company’s headquarters are in Brisbane, California. The Company operates as one reportable segment, Therapeutics, focused on developing and commercializing transformative treatments for patients with serious immunological diseases. On July 7, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to TRUTAKNA® (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

Liquidity

Since inception, the Company has devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, building a sales, marketing and distribution infrastructure to support commercial launch activities, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. The Company has incurred recurring net operating losses and has not generated positive cash flows from operations since its inception and had an accumulated deficit of $1.1 billion as of September 30, 2026. The Company had cash, cash equivalents and marketable securities of $384.0 million as of September 30, 2026. The Company has funded its operations primarily through the issuance of common stock, redeemable convertible preferred stock, debt financing and convertible notes. Management expects to continue to incur losses and negative cash flows from operations in the near term.

Management believes that the Company’s cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund its planned operations and capital expenditure requirements for at least the next 12 months subsequent to the issuance date of these unaudited condensed consolidated financial statements. The Company intends to raise additional capital through public or private equity offerings, debt financing, or other capital sources, which may include strategic collaborations or other arrangements with third parties in order to achieve its long-term business objectives. If the Company fails to obtain necessary capital when needed on acceptable terms, or at all, it could force the Company to delay, limit, reduce or terminate its product development programs, commercialization efforts or other operations.

Net Loss Per Share Attributable to Common Stockholders (Tables)

9 Months Ended

Sep. 30, 2026

Earnings Per Share [Abstract]

Summary of Dilutive Shares Excluded From Computation of Diluted Net Loss Per Share


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Class A common stock options issued and outstanding		9,726,290		8,408,580		9,726,290		8,408,580
Unvested restricted stock units		2,245,765		1,511,420		2,245,765		1,511,420
Shares reserved for ESPP purchases		19,714		18,599		19,714		18,599
Total		11,991,769		9,938,599		11,991,769		9,938,599

Other Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2026	Dec. 31, 2025
Other Financial Statement Information [Abstract]
Prepaid drug manufacturing costs	$ 23,370	$ 1,637
Prepaid clinical trial costs	2,969	3,435
Interest income receivable	2,586	3,285
Prepaid software costs	2,349	1,669
Other	6,910	4,268
Total prepaid expenses and other current assets	$ 38,184	$ 14,294

Stock Compensation

9 Months Ended

Sep. 30, 2026

Share-Based Payment Arrangement [Abstract]

Stock Compensation

8. STOCK COMPENSATION

Equity Plans

2024 Inducement Plan

In February 2024, the Company adopted the 2024 Inducement Plan (Inducement Plan). The Inducement Plan was adopted by the compensation committee of the Company’s board of directors without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) and subsequently amended in August 2024, January 2025, September 2025, and March 2026. In accordance with Rule 5635(c)(4), awards made under the Inducement Plan, including stock options and restricted stock units, may only be granted to newly hired employees as a material inducement to accept employment with the Company. Stock options granted under the Inducement Plan expire no later than ten years from the date of grant.

2021 Equity Incentive Plan and 2017 Equity Incentive Plan

The 2021 Equity Incentive Plan (2021 EIP) and the 2017 Equity Incentive Plan (2017 EIP) became effective in May 2021 and February 2017, respectively. The Company may not grant any additional awards under the 2017 EIP. The 2017 EIP will continue to govern outstanding equity awards granted thereunder. Stock options granted under the 2021 EIP and 2017 EIP expire no later than 10 years from the date of grant.

2021 Employee Stock Purchase Plan

The 2021 Employee Stock Purchase Plan (ESPP) became effective in May 2021. As of September 30, 2026, 270,191 shares have been issued pursuant to the ESPP. The ESPP generally provides for six-month consecutive offering periods beginning every September 14 and March 14. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation.

The table below summarizes the Company's equity plans as of September 30, 2026:


Plan	Maximum Number of Shares Authorized		Shares Available for Future Issuance
2024 Inducement Plan		4,390,000		558,695
2021 Equity Incentive Plan		13,614,767		3,927,855
2017 Equity Incentive Plan		2,275,305		—
2021 Employee Stock Purchase Plan		2,029,448		1,759,257

Option Activity

Stock option activity under the 2017 EIP, 2021 EIP, and 2024 Inducement Plan for the period ended September 30, 2026 is summarized as follows:


	Number of Options			Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value (000s)
Outstanding as of December 31, 2025		8,395,290		$	19.59		7.58	$	260,696
Granted		2,363,500		$	41.28
Exercised		(549,075	)	$	12.09
Cancelled and forfeited		(483,425	)	$	34.85
Outstanding as of September 30, 2026		9,726,290		$	24.52		7.48	$	103,868
Options exercisable as of September 30, 2026		5,282,414		$	17.57		6.48	$	84,344
Vested and expected to vest as of September 30, 2026		9,726,290		$	24.52		7.48	$	103,868

The aggregate intrinsic value of stock options exercised during the three months ended September 30, 2026 and 2025 was $6.4 million and $0.1 million, respectively. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2026 and 2025 was $15.1 million and $3.8 million, respectively. The weighted-average grant date fair value of options granted during the three months ended September 30, 2026 and 2025 was $29.58 per share and $18.31 per share, respectively. The weighted-average grant date fair value of options granted during the nine months ended September 30, 2026 and 2025 was $32.34 per share and $22.56 per share, respectively.

Award Activity

The Company grants restricted stock units (RSU) pursuant to the 2021 EIP and satisfies such grants through the issuance of the Company’s Class A common stock. The following table shows RSU activity for the period ended September 30, 2026:


	Number of Shares			Weighted Average Grant Date Fair Value per Share
Unvested balance as of December 31, 2025		1,599,840		$	28.67
Granted		1,221,627			41.28
Vested		(351,299	)		27.40
Cancelled and forfeited		(224,403	)		33.43
Unvested balance as of September 30, 2026		2,245,765		$	35.25

Stock-Based Compensation Expense


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Research and development	$	6,768	$	4,533	$	20,174	$	12,286
Selling, general and administrative		8,960		5,212		24,625		14,675
Total stock-based compensation expense	$	15,728	$	9,745	$	44,799	$	26,961


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Employees	$	14,767	$	9,267	$	42,601	$	25,103
Non-employees		961		478		2,198		1,858
Total stock-based compensation expense	$	15,728	$	9,745	$	44,799	$	26,961

As of September 30, 2026, the Company had $98.7 million of unrecognized stock-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately 2.6 years. For the three months ended September 30, 2026 and 2025, the Company recognized $10.6 million and $6.9 million of stock-based compensation expense for stock options, respectively. For the nine months ended September 30, 2026 and 2025, the Company recognized $29.8 million and $19.7 million of stock-based compensation expense for stock options, respectively.

As of September 30, 2026, the Company had $67.0 million of unrecognized stock-based compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of approximately 3.0 years. For the three months ended September 30, 2026 and 2025, the Company recognized $4.8 million and $2.7 million of stock-based compensation expense for restricted stock units, respectively. For the nine months ended September 30, 2026 and 2025, the Company recognized $13.9 million and $6.8 million of stock-based compensation expense for restricted stock units, respectively.

Stock-based compensation expense related to the ESPP for the three months ended September 30, 2026 and 2025 was $0.3 million and $0.1 million, respectively. Stock-based compensation expense related to the ESPP for the nine months ended September 30, 2026 and 2025 was $1.0 million and $0.4 million, respectively.


	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Expected term (in years)	6.0 – 6.1	6.0 – 6.1	5.5 – 6.1	5.5 – 6.1
Expected volatility	79.6% – 80.9%	81.9% – 82.3%	78.1% – 87.6%	81.8% – 83.9%
Risk-free rate	4.3% – 5.1%	3.8% – 4.1%	3.7% – 5.1%	3.8% – 4.5%
Dividend yield	—	—	—	—

Licenses And Intangible Assets (Table)

9 Months Ended

Sep. 30, 2026

Licenses [Abstract]

Intangible Asset, Finite-Lived [Table Text Block]

Intangible assets, net consist of the following (in thousands, except years):


	September 30, 2026								December 31, 2025
	Weighted-Average Remaining Life	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Weighted-Average Remaining Life	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Finite-lived intangible assets
Acquired intellectual property	14.7 years	$	20,000	$	(335	)	$	19,665	N/A	$	—	$	—	$	—
Acquired internal-use software	1.9 years		953		(119	)		834	N/A		—		—		—
Total		$	20,953	$	(454	)	$	20,499		$	—	$	—	$	—

Intangible Asset, Finite-Lived, Amortization Expense [Table Text Block]

As of September 30, 2026, the estimated future amortization expense associated with the Company’s finite-lived intangible assets was as follows:


2026 (remaining)	$	444
2027		1,776
2028		1,631
2029		1,341
2030		1,341
Thereafter		13,966
Total estimated future amortization expense	$	20,499

Segment Reporting - Schedule of Segment Operating Expenses Including Segment Expenses, and Net Loss (Parenthetical) (Details)	9 Months Ended
	Sep. 30, 2026
Segment Reporting [Abstract]
Other segment items composition description	Other segment items included in net loss consist of currency exchange gains and losses and other income/expense.

Stockholders' Equity - Additional Information (Details) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2025	Sep. 30, 2026	Dec. 31, 2025
Class Of Stock [Line Items]
Preferred stock shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Net proceeds from this follow-on public offering	$ 281,300,000
Common Class A [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	500,000,000	500,000,000	500,000,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock conversion basis		one	one
Cash dividends		$ 0
Common stock, Shares outstanding	71,267,429	72,287,904	71,267,429
Common stock issued pursuant to underwriters option shares	920,716
Common Class A [Member] \| Follow-on Public Offering [Member]
Class Of Stock [Line Items]
Stock shares issued during the period new issues shares	7,058,824
Sale of stock, price per share	$ 42.5		$ 42.5
Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized	14,600,000	14,600,000	14,600,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Cash dividends		$ 0
Common stock, Shares outstanding	0	0	0

Stock Compensation - Summary of Company's Equity Plans (Details)	9 Months Ended
	Sep. 30, 2026 shares
2024 Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of shares authorized	4,390,000
Shares available for future issuance	558,695
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of shares authorized	13,614,767
Shares available for future issuance	3,927,855
2017 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of shares authorized	2,275,305
Shares available for future issuance	0
2021 Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Maximum number of shares authorized	2,029,448
Shares available for future issuance	1,759,257

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

- Definition

Number of shares issued during the period as a result of an employee stock purchase plan.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

+ Details

Other Financial Statement Information (Tables)

9 Months Ended

Sep. 30, 2026

Other Financial Statement Information [Abstract]

Schedule of Inventory

Inventory consists of the following (in thousands):


	September 30, 2026		December 31, 2025
Raw materials	$	5,799	$	—
Work in process		929		—
Finished goods		350		—
Total inventory	$	7,078	$	—

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	September 30, 2026		December 31, 2025
Prepaid drug manufacturing costs	$	23,370	$	1,637
Prepaid clinical trial costs		2,969		3,435
Interest income receivable		2,586		3,285
Prepaid software costs		2,349		1,669
Other		6,910		4,268
Total prepaid expenses and other current assets	$	38,184	$	14,294

Schedule of Accrued Expenses And Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):


	September 30, 2026		December 31, 2025
Accrued payroll	$	15,036	$	18,700
Accrued drug manufacturing costs		6,408		8,427
Accrued clinical trial costs		4,678		1,333
Accrued commercial planning, sales and marketing expenses		3,516		1,181
Sales discounts, rebates, and allowances		1,703		—
Accrued royalties		1,439		—
Other		2,822		1,916
Total accrued expenses and other current liabilities	$	35,602	$	31,557

Segment Reporting - Schedule of Segment Operating Expenses Including Segment Expenses, and Net Loss (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2026

Jun. 30, 2026

Mar. 31, 2026

Sep. 30, 2025

Jun. 30, 2025

Mar. 31, 2025

Sep. 30, 2026

Sep. 30, 2025

Segment Reporting [Line Items]

Product revenue, net

$ 10,277

$ 0

$ 10,277

$ 0

Operating expenses:

Cost of sales

3,296

Direct research and development

41,253

56,473

187,344

155,946

Total operating expenses

105,979

83,932

343,601

221,267

Loss from operations

(95,702)

(83,932)

(333,324)

(221,267)

Other income (expense):

Interest income

4,336

5,736

16,039

18,962

Interest expense

(1,873)

(1,960)

(5,544)

(5,627)

Net loss

(93,711)

$ (109,473)

$ (121,032)

(80,293)

$ (76,531)

$ (51,694)

(324,216)

(208,518)

Operating Segments [Member]

Segment Reporting [Line Items]

Product revenue, net

10,277

Operating expenses:

Cost of sales

3,296

Payroll and related

47,380

29,240

137,964

75,189

Commercial expenses

14,458

5,716

37,498

12,485

Depreciation and amortization

243

129

515

333

Other segment items*

^[1]

19,924

16,472

53,123

43,215

Total operating expenses

105,979

83,932

343,601

221,267

Loss from operations

(95,702)

(83,932)

(333,324)

(221,267)

Other income (expense):

Interest income

4,336

5,736

16,039

18,962

Interest expense

(1,873)

(1,960)

(5,544)

(5,627)

Other segment items**

^[2]

(472)

(137)

(1,387)

(586)

Net loss

(93,711)

(80,293)

(324,216)

(208,518)

Operating Segments [Member] | Clinical Trials [Member]

Operating expenses:

Direct research and development

14,047

10,466

58,377

35,096

Operating Segments [Member] | Contract Manufacturing [Member]

Operating expenses:

Direct research and development

$ 6,631

$ 21,909

$ 52,828

$ 54,949

[1]	*Other segment items included in total operating expenses primarily consist of consulting and contractors, professional services, equipment and software, travel and entertainment, facilities, medical affairs, and corporate communications.
[2]	**Other segment items included in net loss consist of currency exchange gains and losses and other income/expense.

Stock Compensation - Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2026 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested, Beginning balance \| shares	1,599,840
Granted \| shares	1,221,627
Vested \| shares	(351,299)
Cancelled and forfeited \| shares	(224,403)
Unvested, Ending balance \| shares	2,245,765
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 28.67
Weighted Average Grant Date Fair Value, Granted \| $ / shares	41.28
Weighted Average Grant Date Fair Value, Vested \| $ / shares	27.4
Weighted Average Grant Date Fair Value, Cancelled and Forfeited \| $ / shares	33.43
Weighted Average Grant Date Fair Value, Ending Balance \| $ / shares	$ 35.25

Related Party Transactions

9 Months Ended

Sep. 30, 2026

Related Party Transactions

11. RELATED PARTY TRANSACTIONS

A member of the Company’s board of directors also serves as chairman of the board of directors of IntegriChain. The Company entered into an agreement with IntegriChain to procure software and services for government pricing, contracting, policy development, and rebate operations related to commercialization and market access with expected fees and expenses of up to $0.4 million. The Company recorded related party expense of $0.1 million and $0.2 million to IntegriChain for these services in the three and nine months ended September 30, 2026, respectively. This amount is included in selling, general and administrative expenses in the Company’s condensed consolidated statements of operations and comprehensive loss. As of September 30, 2026, the Company recorded related party payable amounts of $0.3 million to IntegriChain, which were included in accounts payable and other current liabilities in the Company’s condensed consolidated balance sheet.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(7)(e)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Stock Compensation - Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 15,728	$ 9,745	$ 44,799	$ 26,961
Employees [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	14,767	9,267	42,601	25,103
Non-employees [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	961	478	2,198	1,858
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	6,768	4,533	20,174	12,286
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 8,960	$ 5,212	$ 24,625	$ 14,675

Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	11,991,769	9,938,599	11,991,769	9,938,599
Class A Common Stock Options Issued and Outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	9,726,290	8,408,580	9,726,290	8,408,580
Unvested Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	2,245,765	1,511,420	2,245,765	1,511,420
Shares Reserved For ESPP Purchases
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	19,714	18,599	19,714	18,599

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Related Party Transaction [Line Items]
Related party expense	$ 105,979	$ 83,932	$ 343,601	$ 221,267
IntegriChain [Member]
Related Party Transaction [Line Items]
Fees and expenses			400
Related Party [Member] \| IntegriChain [Member]
Related Party Transaction [Line Items]
Related party expense	100		200
Related party payable amount	$ 300		$ 300

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(7)(e)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 970
-SubTopic 810
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477383/970-810-45-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false